Table 1.
Selected baseline demographic and clinical characteristic of the sample, overall and by type of anti-IL23.
| Variables | Overall sample (n=427) | Guselkumab (n=201) | Risankizumab (n=116) | Tildrakizumab (n=110) | p* |
|---|---|---|---|---|---|
| Mean age in years (SD) | 54.3 (14.7) | 52.8 (14.6) | 56.0 (13.6) | 55.2 (15.7) | |
| Male gender, % | 63.2 | 60.7 | 62.9 | 68.2 | |
| Mean BMI (SD) | 27.9 (5.2) | 27.8 (5.4) | 27.9 (5.0) | 28.2 (5.0) | |
| Current smoker, % | 58.4 | 49.4 | 68.5 | 63.6 | a, b |
| Comorbidities, % | |||||
| None | 36.1 | 36.3 | 31.9 | 40.0 | |
| One | 43.3 | 38.8 | 50.9 | 43.6 | a |
| Two | 17.3 | 19.4 | 15.5 | 15.5 | |
| Three or more | 3.3 | 5.5 | 1.7 | 0.9 | b, c |
| Mean length of disease in years (SD) | 20.6 (12.4) | 20.1 (12.5) | 21.7 (12.2) | 20.2 (12.6) | |
| Mean age at onset (SD) | 33.3 (16.0) | 32.3 (16.2) | 33.7 (14.4) | 34.8 (17.2) | |
| Concomitant arthritis, % | 27.3 | 30.8 | 28.7 | 19.3 | b |
| Psoriasis type, % | |||||
| Vulgaris | 84.0 | 84.6 | 80.9 | 86.4 | |
| Inverse | 3.1 | 2.5 | 0.8 | 6.4 | a, b, c |
| OthersA | 4.9 | 3.4 | 7.0 | 5.4 | |
| CompositeB | 8.0 | 9.5 | 11.3 | 1.8 | b |
| Psoriasis site, % | |||||
| Typical | 58.8 | 58.7 | 44.8 | 73.6 | a, b, c |
| Folds | 27.2 | 28.8 | 35.3 | 15.5 | b, c |
| Hands and feet | 11.7 | 10.0 | 16.4 | 10.0 | |
| Others (nails, scalp, genital) | 2.3 | 2.5 | 3.5 | 0.9 | |
| Number of previous traditional treatments, % | |||||
| None | 4.2 | 4.0 | 1.7 | 7.3 | |
| One | 31.6 | 28.9 | 29.3 | 39.1 | |
| Two | 34.2 | 33.3 | 33.6 | 36.4 | |
| Three or more | 30.0 | 33.8 | 35.3 | 17.3 | |
| Number of previous biologic treatments, % | (N=395) | (N=189) | (N=111) | (N=95) | |
| None | 24.8 | 23.8 | 26.1 | 25.3 | |
| One | 29.9 | 23.3 | 24.3 | 49.5 | |
| Two | 21.3 | 22.2 | 25.2 | 14.7 | b |
| Three or more | 24.0 | 30.7 | 24.3 | 10.5 | b |
| Median duration of previous biologic treatments in months (IQR) | 29.0 (69.5) | 35.0 (69.0) | 40.0 (60.0) | 14.5 (24.0) | |
| Mean PASI at baseline (SD) | 12.9 (7.3) | 13.5 (7.6) | 11.9 (7.1) | 12.9 (6.8) | |
SD: Standard deviation; IQR: Interquartile range. PASI: Psoriasis area severity index.
Guttate, pustular, or erythrodermic psoriasis;
More than one type of psoriasis concomitantly reported.
Chi-squared test for categorical variables; one-way ANOVA with Sidak corrections for continuous ones.
a: p<0.05 for the comparison between patients treated with Guselkumab and patients treated with Risankizumab; b: p<0.05 for the comparison between patients treated with Guselkumab and patients treated with Tildrakizumab; c: p<0.05 for the comparison between patients treated with Risankizumab and patients treated with Tildrakizumab. All p-values that are not indicated were ≥0.05.